“It was basically eating my bone and compromising my tibia, and it will keep growing and growing and growing. It doesn’t stop.” Giant cell tumors are literally a one-in-a-million ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

Chordoma, giant cell tumor, undifferentiated pleomorphic sarcoma, adamantinoma and fibrosarcoma are also types of primary bone cancer; however, they are fewer in number. In India, bone cancer ...

Osenvelt is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

TGCT is a rare, non-malignant tumor that develops inside or near joints. TGCT is caused by dysregulation of the CSF1 gene leading to overproduction of CSF1. TGCT is also known as giant cell tumor ...

Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of ...

and can be prescribed to treat skeletal-related events for patients with multiple myeloma and those with bone metastases from solid tumors, to treat adults and adolescents with a giant cell tumor ...

On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places Ono in ...

Background: To report the outcomes of computer-aided resection and endoprosthesis design for the management of malignant bone tumors around the knee. Methods: Computed tomography (CT) and magnetic ...

to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia ...